Startup BioLizard will develop the algorithm to help Novigenix migrate its immuno-transcriptiomic assay for early colorectal cancer detection to a new NGS-based platform.
Tempus is eligible for milestone payments and royalties for any oncology therapeutics Genmab might develop based on their joint research projects.
The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.
In an abstract to be presented at ASHG, Baylor Genetics researchers will discuss how Emedgene's AI-driven platform helped them streamline and standardize sequencing review.
The longtime quest of one Microsoft data scientist to stop infant crib deaths has grown into a genomics and AI research program with lofty goals.
Invitae sees Jungla's AI platform as complementary to its own variant classification and interpretation methods.
The firms aim to combine PerkinElmer 's Ordered Data Interpretation Network and FDNA's Face2Gene facial analysis software to target emerging markets.
With $200M in new investment, the precision medicine firm has launched a clinical trial matching service, is adding clinical data to TCGA, and is moving into the Asian market.
The Center for Genomic Health will be one facet of the new James Center for Artificial Intelligence and Human Health, funded by a philanthropic gift.
This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.